NAV

nor-NOHA

Identification

Generic Name
nor-NOHA
DrugBank Accession Number
DB02381
Background

N-Hydroxy-nor-L-arginine (nor-NOHA) is under investigation in clinical trial NCT02009527 (Arginase Inhibition in Ischemia-reperfusion Injury).

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 176.1738
Monoisotopic: 176.09094027
Chemical Formula
C5H12N4O3
Synonyms
  • (2S)-2-amino-4-(((hydroxyamino)iminomethyl)amino)butanoic acid
  • N-hydroxy-nor-arginine
  • N-hydroxy-nor-L-arginine
  • Nomega-Hydroxy-nor-L-arginine
External IDs
  • J842.499C
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UArginase-1Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as l-alpha-amino acids. These are alpha amino acids which have the L-configuration of the alpha-carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
L-alpha-amino acids
Alternative Parents
N-hydroxyguanidines / Fatty acids and conjugates / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Carboximidamides / Organopnictogen compounds / Organic oxides / Monoalkylamines / Imines
show 2 more
Substituents
Aliphatic acyclic compound / Amine / Amino acid / Carbonyl group / Carboximidamide / Carboxylic acid / Fatty acid / Guanidine / Hydrocarbon derivative / Imine
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
U0F1149OFR
CAS number
189302-40-7
InChI Key
KOBHCUDVWOTEKO-VKHMYHEASA-N
InChI
InChI=1S/C5H12N4O3/c6-3(4(10)11)1-2-8-5(7)9-12/h3,12H,1-2,6H2,(H,10,11)(H3,7,8,9)/t3-/m0/s1
IUPAC Name
(2S)-2-amino-4-(N'-hydroxycarbamimidamido)butanoic acid
SMILES
N[C@@H](CCNC(=N)NO)C(O)=O

References

General References
Not Available
PubChem Compound
446124
PubChem Substance
46505343
ChemSpider
393563
BindingDB
50008099
ChEMBL
CHEMBL1234777
ZINC
ZINC000002244322
PDBe Ligand
NNH
PDB Entries
1hqh / 3kv2 / 4iu1 / 4q3u / 7xmn

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceCoronary Artery Disease (CAD) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.24 mg/mLALOGPS
logP-3.6ALOGPS
logP-3.7Chemaxon
logS-1.9ALOGPS
pKa (Strongest Acidic)2.08Chemaxon
pKa (Strongest Basic)10.56Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count6Chemaxon
Polar Surface Area131.46 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity61.54 m3·mol-1Chemaxon
Polarizability16.73 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9049
Blood Brain Barrier+0.5644
Caco-2 permeable-0.6693
P-glycoprotein substrateNon-substrate0.6016
P-glycoprotein inhibitor INon-inhibitor0.9533
P-glycoprotein inhibitor IINon-inhibitor0.9435
Renal organic cation transporterNon-inhibitor0.8299
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.7585
CYP450 3A4 substrateNon-substrate0.7623
CYP450 1A2 substrateNon-inhibitor0.8796
CYP450 2C9 inhibitorNon-inhibitor0.8783
CYP450 2D6 inhibitorNon-inhibitor0.8968
CYP450 2C19 inhibitorNon-inhibitor0.8421
CYP450 3A4 inhibitorNon-inhibitor0.8323
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9857
Ames testAMES toxic0.7725
CarcinogenicityNon-carcinogens0.8281
BiodegradationReady biodegradable0.6976
Rat acute toxicity2.1334 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9613
hERG inhibition (predictor II)Non-inhibitor0.9325
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0543-9300000000-985429ac21264690caca
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-1900000000-f034cfe5346e722f66d6
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0gb9-1900000000-48e51f39c0b5d20eee02
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0pdi-9700000000-85f33c5a401e1dff3c22
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0f6x-9700000000-4bafe0001c6d7e53a27b
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9200000000-03511d2aa0350a03f08a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-8f6233dcf511512ed61e
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-146.7367723
predicted
DarkChem Lite v0.1.0
[M-H]-131.28825
predicted
DeepCCS 1.0 (2019)
[M+H]+147.0873723
predicted
DarkChem Lite v0.1.0
[M+H]+135.11559
predicted
DeepCCS 1.0 (2019)
[M+Na]+147.1780723
predicted
DarkChem Lite v0.1.0
[M+Na]+144.42111
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Arginase-1
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Manganese ion binding
Specific Function
Not Available
Gene Name
ARG1
Uniprot ID
P05089
Uniprot Name
Arginase-1
Molecular Weight
34734.655 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created at June 13, 2005 13:24 / Updated at July 02, 2020 13:15